fbpx

Brain Cancer

Midline Glioblastoma

Female, 36 years

Patient Internal 434626791

ICD-10 code

C71.7 Malignant Neoplasm of Brain Stem

Diagnosis (Incl. Metastases/Stage) and Year

May 2021
Midline Glioma, WHO Grade 4, likely H3K27M Mutation, IDH1/2 mutations not detected, TERT (-).
Disease progression in June 2023.

Previous Treatment

Surgery, Radiation Therapy, Chemotherapy (Temozolomide), Chemotherapy (Lomustine).

Prognosis and Survival Expectation

The prognosis remains poor, with a median survival of ~14 months from diagnosis.

Treatment Provided

Autologous DCV (4 doses) and CIK (16 doses) over a period of 14 months.

Patient Survival/Condition and Year
Date of Review: 15/11/2023

The patient has survived for 29 months. It can be concluded that the addition of Immunotherapy, alongside Surgery, Radiation Therapy and Chemotherapy, has benefited in disease stabilisation and extended survival by an estimate of 15 months so far.

Disclaimer

We encourage you to learn more about your condition and treatment options to make informed decisions about your healthcare. However, please keep in mind that not all information available online or in other sources is accurate or relevant to your specific situation. It’s important to rely on credible, evidence-based sources such as official medical websites, peer-reviewed publications, or information provided by professional healthcare organizations. Always discuss any information you find with your healthcare provider before making decisions, as they can help clarify details, address concerns, and ensure the information is appropriate for your unique needs.

Ok